Banner

Breast Cancer Monoclonal Antibodies Global Market Report 2022 – By Product (Naked Mabs, Conjugated Mabs), By End-User (Hospitals, Retail Pharmacies), By Treatment (Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy) – Market Size, Trends, And Global Forecast 2022-2026

Starting Price : $5000.00 | Pages : 150 | Published : October 2022 | SKU CODE : 7723 | Delivery Time: 2-3 business days | Format :


The breast cancer monoclonal antibodies (mAbs) market consists of sales of monoclonal antibodies by entities (organizations, sole traders, and partnerships) that produce breast cancer monoclonal antibodies used as therapy for breast cancer either as monotherapy or combination therapy. The revenue generated includes the sales of naked mAbs and conjugated mAbs. The companies engaged in the breast cancer monoclonal antibodies market are primarily focused on the research, development, and production of monoclonal antibodies that are used in early-stage and advanced breast cancer, ductal carcinoma in-situ, triple-negative breast cancer, inflammatory breast cancer, and others.

The main types of breast cancer monoclonal antibodies are naked mAbs and conjugated mAbs. Naked mAbs are antibodies that are free of any drugs or radioactive materials. They are self-contained. The most prevalent type of mAb used to fight cancer is this one. The different types of treatments include chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, and hormone therapy and are used in various sectors such as hospitals, and retail pharmacies.

The breast cancer monoclonal antibodies (mAbs) market research report is one of a series of new reports from The Business Research Company that provides breast cancer monoclonal antibodies (mAbs) market statistics, including breast cancer monoclonal antibodies (mAbs) industry global market size, regional shares, competitors with a breast cancer monoclonal antibodies (mAbs) market share, detailed breast cancer monoclonal antibodies (mAbs) market segments, market trends and opportunities, and any further data you may need to thrive in the breast cancer monoclonal antibodies (mAbs) industry. This breast cancer monoclonal antibodies (mAbs) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The global breast cancer monoclonal antibodies market is expected to grow from $15.37 billion in 2021 to $16.67 billion in 2022 at a compound annual growth rate (CAGR) of 8.5%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, affecting many markets across the globe. The breast cancer monoclonal antibodies (mAbs) market is expected to reach $21.47 billion in 2026 at a CAGR of 6.5%.

Rising breast cancer incidences are expected to drive the breast cancer monoclonal antibodies market’s growth. According to the American Cancer Society, there were 1.7 million new cases and 0.6 million cancer deaths in 2019 in the USA. As of January 2020, there were more than 3.5 million women with a history of breast cancer in the US. This includes women currently being treated and women who have completed the treatment. According to the American cancer society, approximately 500 men and 41,760 women died of breast cancer in 2019. Thus, the rising prevalence of breast cancer globally is expected to boost the growth of the breast cancer monoclonal antibodies market.

Alternative treatment methods and natural remedies are increasingly becoming popular globally and this is expected to impact the revenues of breast cancer monoclonal antibodies manufacturing companies. Treatments in the fields of homeopathy, Ayurveda, yoga, acupuncture, and sujok therapy are gaining popularity and slowly replacing some traditional hospital practices. For instance, ayurvedic medicine, an ancient Indian system of medicine uses a range of techniques and treatments for cancer. Many herbs used in Ayurveda have anti-cancer properties. According to the World Health Organization (WHO), some nations are still responding to plant-based treatment as their main medicine source, and developing nations are using the benefits of natural compounds for therapeutic purposes, affecting the sales of oncology drugs. Also, the global homeopathic product market is projected to reach $18.6 billion by the end of 2027. The National Institute of Cancer indicated the promising results of vaccines in HER2-positive cancer including breast, ovarian, lung, colorectal, and gastroesophageal cancers, wherein they have used patients’ immune cells to treat their HER2-positive cancers by genetically modifying them to customize personalized vaccines. These factors are expected to continue during the forecast period and limit the demand for the breast cancer monoclonal antibodies market.

Companies in the breast cancer monoclonal antibodies market are investing in targeted and combination therapy, which has proven to be more effective and less toxic than the traditional treatment options. Targeted cancer therapies are drugs or substances that block the growth of cancer by interfering with molecules that are more specifically involved in cancer cell progression than in normal cell activity. The goal of these therapies is to eliminate cancerous cells in the body while leaving normal cells unharmed. By focusing on changes in the cell that are specific to cancer, this therapy may prove to be more effective than traditional chemotherapy and radiotherapy. Combination therapy uses a treatment method in which a patient is given two or more drugs (or other therapeutic agents) for a single disease. In February 2019, the FDA approved the combination of a mAb trastuzumab with hyaluronidase-oysk for SC administration in HER2-positive early breast cancer wherein hyaluronidase is an enzyme that helps the body to use trastuzumab. In 2020, The American Society of Clinical Oncology published the success of combination therapy of a targeted monoclonal antibody atezolizumab with chemotherapy with improved progression-free survival in patients with triple-negative breast cancer. It resulted in progression-free survival of 7.2 months for patients receiving the combination therapy, compared with 5.5 months for those who received a placebo plus nab-paclitaxel (chemotherapy). Promising results with targeted therapies and combination therapies are expected to raise the focus on these therapies in the breast cancer monoclonal antibodies market.

In March 2019, AstraZeneca, a UK-based global biopharmaceutical company that discovers, develops and commercializes prescription drugs in therapy areas such as oncology, cardiovascular, renal & metabolism, and respiratory, entered into a collaboration with Daiichi Sankyo Company, Limited with an upfront payment of $1.35 billion. The collaboration agreement is about the global development and commercialization of trastuzumab deruxtecan (DS-8201), which is an exclusive antibody-drug conjugate (ADC) and potential new targeted cancer therapy. Except in Japan (exclusive rights for Daiichi Sankyo), the companies will jointly develop and commercialize trastuzumab deruxtecan. Daiichi Sankyo Company Limited is a Japan-based global pharmaceutical company that creates innovative new and generic medicines and new methods of drug discovery and delivery.

Major players in the breast cancer monoclonal antibodies (mAbs) market are Amgen, Mylan, Merck, Novartis, GlaxoSmithKline, Daiichi Sankyo, Biocad, Boehringer Ingelheim, Bristol-Myers Squibb, and Array BioPharma.

The regions covered in the breast cancer monoclonal antibodies (mAbs) market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the breast cancer monoclonal antibodies (mAbs) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

The global breast cancer monoclonal antibodies market is segmented -

1) By Product: Naked Mabs, Conjugated Mabs

2) By End-User: Hospitals, Retail Pharmacies

3) By Treatment: Chemotherapy, Surgery & Radiation Therapy, Targeted Therapy, Biologic Therapy, Hormone Therapy

    Table Of Contents

    1. Executive Summary

    2. Breast Cancer Monoclonal Antibodies Market Characteristics

    3. Breast Cancer Monoclonal Antibodies Market Trends And Strategies

    4. Breast Cancer Monoclonal Antibodies Market – Macro Economic Scenario

    4.1 COVID-19 Impact On Breast Cancer Monoclonal Antibodies Market

    4.2 Ukraine-Russia War Impact On Breast Cancer Monoclonal Antibodies Market

    4.3 Impact Of High Inflation On Breast Cancer Monoclonal Antibodies Market

    5. Breast Cancer Monoclonal Antibodies Market Size And Growth

    5.1. Global Breast Cancer Monoclonal Antibodies Historic Market, 2016-2021, $ Billion

    5.1.1. Drivers Of The Market

    5.1.2. Restraints On The Market

    5.2. Global Breast Cancer Monoclonal Antibodies Forecast Market, 2021-2026F, 2031F, $ Billion

    5.2.1. Drivers Of The Market

    5.2.2. Restraints On the Market

    6. Breast Cancer Monoclonal Antibodies Market Segmentation

    6.1. Global Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Naked Mabs

    Conjugated Mabs

    6.2. Global Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Hospitals

    Retail Pharmacies

    6.3. Global Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    Chemotherapy

    Surgery & Radiation Therapy

    Targeted Therapy

    Biologic Therapy

    Hormone Therapy

    7. Breast Cancer Monoclonal Antibodies Market Regional And Country Analysis

    7.1. Global Breast Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    7.2. Global Breast Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8. Asia-Pacific Breast Cancer Monoclonal Antibodies Market

    8.1. Asia-Pacific Breast Cancer Monoclonal Antibodies Market Overview

    Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies

    8.2. Asia-Pacific Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    8.3. Asia-Pacific Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    9. China Breast Cancer Monoclonal Antibodies Market

    9.1. China Breast Cancer Monoclonal Antibodies Market Overview

    9.2. China Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    9.3. China Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F,$ Billion

    10. India Breast Cancer Monoclonal Antibodies Market

    10.1. India Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    10.2. India Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11. Japan Breast Cancer Monoclonal Antibodies Market

    11.1. Japan Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    11.2. Japan Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12. Australia Breast Cancer Monoclonal Antibodies Market

    12.1. Australia Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    12.2. Australia Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13. Indonesia Breast Cancer Monoclonal Antibodies Market

    13.1. Indonesia Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    13.2. Indonesia Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14. South Korea Breast Cancer Monoclonal Antibodies Market

    14.1. South Korea Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    14.2. South Korea Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15. Western Europe Breast Cancer Monoclonal Antibodies Market

    15.1. Western Europe Breast Cancer Monoclonal Antibodies Market Overview

    15.2. Western Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    15.3. Western Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16. UK Breast Cancer Monoclonal Antibodies Market

    16.1. UK Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    16.2. UK Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17. Germany Breast Cancer Monoclonal Antibodies Market

    17.1. Germany Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    17.2. Germany Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18. France Breast Cancer Monoclonal Antibodies Market

    18.4. France Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    18.5. France Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19. Eastern Europe Breast Cancer Monoclonal Antibodies Market

    19.1. Eastern Europe Breast Cancer Monoclonal Antibodies Market Overview

    19.2. Eastern Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    19.3. Eastern Europe Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20. Russia Breast Cancer Monoclonal Antibodies Market

    20.1. Russia Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    20.2. Russia Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21. North America Breast Cancer Monoclonal Antibodies Market

    21.1. North America Breast Cancer Monoclonal Antibodies Market Overview

    21.2. North America Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    21.3. North America Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22. USA Breast Cancer Monoclonal Antibodies Market

    22.1. USA Breast Cancer Monoclonal Antibodies Market Overview

    22.2. USA Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    22.3. USA Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23. South America Breast Cancer Monoclonal Antibodies Market

    23.1. South America Breast Cancer Monoclonal Antibodies Market Overview

    23.2. South America Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    23.3. South America Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24. Brazil Breast Cancer Monoclonal Antibodies Market

    24.1. Brazil Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    24.2. Brazil Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25. Middle East Breast Cancer Monoclonal Antibodies Market

    25.1. Middle East Breast Cancer Monoclonal Antibodies Market Overview

    25.2. Middle East Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    25.3. Middle East Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26. Africa Breast Cancer Monoclonal Antibodies Market

    26.1. Africa Breast Cancer Monoclonal Antibodies Market Overview

    26.2. Africa Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    26.3. Africa Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion

    27. Breast Cancer Monoclonal Antibodies Market Competitive Landscape And Company Profiles

    27.1. Breast Cancer Monoclonal Antibodies Market Competitive Landscape

    27.2. Breast Cancer Monoclonal Antibodies Market Company Profiles

    27.2.1. Amgen

    27.2.1.1. Overview

    27.2.1.2. Products and Services

    27.2.1.3. Strategy

    27.2.1.4. Financial Performance

    27.2.2. Mylan

    27.2.2.1. Overview

    27.2.2.2. Products and Services

    27.2.2.3. Strategy

    27.2.2.4. Financial Performance

    27.2.3. Merck

    27.2.3.1. Overview

    27.2.3.2. Products and Services

    27.2.3.3. Strategy

    27.2.3.4. Financial Performance

    27.2.4. Novartis

    27.2.4.1. Overview

    27.2.4.2. Products and Services

    27.2.4.3. Strategy

    27.2.4.4. Financial Performance

    27.2.5. GlaxoSmithKline

    27.2.5.1. Overview

    27.2.5.2. Products and Services

    27.2.5.3. Strategy

    27.2.5.4. Financial Performance

    28. Breast Cancer Monoclonal Antibodies Pipeline Analysis

    29. Key Mergers And Acquisitions In The Breast Cancer Monoclonal Antibodies Market

    30. Breast Cancer Monoclonal Antibodies Market Future Outlook and Potential Analysis

    31. Appendix

    31.1. Abbreviations

    31.2. Currencies

    31.3. Historic And Forecast Inflation Rates

    31.4. Research Inquiries

    31.5. The Business Research Company

    31.6. Copyright And Disclaimer

List Of Tables

    Table 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Table 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Table 3: Global Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 4: Global Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 5: Global Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 6: Global Breast Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 7: Global Breast Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 8: Asia-Pacific, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 9: Asia-Pacific, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 10: China, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 11: China, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 12: India, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 13: India, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 14: Japan, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 15: Japan, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 16: Australia, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 17: Australia, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 18: Indonesia, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 19: Indonesia, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 20: South Korea, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 21: South Korea, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 22: Western Europe, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 23: Western Europe, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 24: UK, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 25: UK, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 26: Germany, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 27: Germany, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 28: France, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 29: France, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 30: Eastern Europe, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 31: Eastern Europe, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 32: Russia, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 33: Russia, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 34: North America, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 35: North America, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 36: USA, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 37: USA, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 38: South America, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 39: South America, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 40: Brazil, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 41: Brazil, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 42: Middle East, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 43: Middle East, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 44: Africa, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 45: Africa, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Table 46: Amgen Financial Performance
  • Table 47: Mylan Financial Performance
  • Table 48: Merck Financial Performance
  • Table 49: Novartis Financial Performance
  • Table 50: GlaxoSmithKline Financial Performance

List Of Figures

    Figure 1: Global Historic Market Growth, 2016-2021, $ Billion
  • Figure 2: Global Forecast Market Growth, 2021-2026F, 2031F, $ Billion
  • Figure 3: Global Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 4: Global Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 5: Global Breast Cancer Monoclonal Antibodies Market, Segmentation By Treatment, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 6: Global Breast Cancer Monoclonal Antibodies Market, Split By Region, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 7: Global Breast Cancer Monoclonal Antibodies Market, Split By Country, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 8: Asia-Pacific, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 9: Asia-Pacific, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 10: China, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 11: China, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 12: India, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 13: India, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 14: Japan, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 15: Japan, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 16: Australia, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 17: Australia, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 18: Indonesia, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 19: Indonesia, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 20: South Korea, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 21: South Korea, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 22: Western Europe, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 23: Western Europe, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 24: UK, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 25: UK, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 26: Germany, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 27: Germany, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 28: France, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 29: France, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 30: Eastern Europe, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 31: Eastern Europe, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 32: Russia, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 33: Russia, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 34: North America, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 35: North America, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 36: USA, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 37: USA, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 38: South America, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 39: South America, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 40: Brazil, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 41: Brazil, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 42: Middle East, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 43: Middle East, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 44: Africa, Breast Cancer Monoclonal Antibodies Market, Segmentation By Product, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 45: Africa, Breast Cancer Monoclonal Antibodies Market, Segmentation By End-User, Historic and Forecast, 2016-2021, 2021-2026F, 2031F, $ Billion
  • Figure 46: Amgen Financial Performance
  • Figure 47: Mylan Financial Performance
  • Figure 48: Merck Financial Performance
  • Figure 49: Novartis Financial Performance
  • Figure 50: GlaxoSmithKline Financial Performance
The Business Research Company offers the dermatitis market research report 2022 with industry size, share, segments and market growth
The Business Research Company offers the insulin drugs market research report 2022 with industry size, share, segments and market growth
The Business Research Company offers the anti-parkinson drugs market research report 2022 with industry size, share, segments and market growth
The Business Research Company offers the pancreatic cancer drugs market research report 2022 with industry size, share, segments and market growth
Best Prospects in the Global Hormonal Contraceptives Market and Strategies for Growth – Includes Hormonal Contraceptives Market Share
Take Up Global Biosimilars Market Opportunities With Clear Industry Data – Includes Biosimilars Market Size
Take Up Global Nucleic Acid Based Gene Therapy Market Opportunities with Clear Industry Data – Includes Nucleic Acid Based Gene Therapy Market Size
Global Enzyme Inhibitor Market Overview And Prospects – Includes Enzyme Inhibitor Market Share
Breast Cancer Diagnostics Global Market Report 2022 – By Type (Imaging, Biopsy, Genomic Tests, Blood Tests), By Technology (Fluorescent In Situ Hybridization (FISH), Comparative Genomic Hybridization (CGH), Immunohistochemical (IHC)), By Cancer Type (BRCA Breast Cancer, ER & PR Breast Cancer, HER 2 Breast Cancer, EGFR Mutation Test Breast Cancer), By Diagnostic Type (Ionizing Breast Imaging Technologies, Non-ionizing Imaging Technologies), By End-User (Hospitals and Clinics, Cancer Research Centers, Diagnostic Laboratories, Ambulatory Surgical Centers) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Breast Imaging Devices Global Market Report 2022 – By Product Type (Tomosynthesis, Breast Ultrasound, Breast MRI, Mammography, Nuclear Imaging, Other Product Types), By Technology (Ionizing, Non Ionizing), By End User (Hospitals & Clinics, Breast Care Centers, Diagnostic Imaging Centers) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Research Antibodies and Reagents Global Market Report 2022 – By Technology (Western Blot, Immunofluorescence, Immunohistochemistry, Flow Cytometry, Enzyme-linked Immunosorbent Assay (ELISA), Multiplex Immunosorbent Assay, Immunoprecipitation), By Application (Proteomics, Drug Discovery & Development, Genomics), By End-User (Pharmaceutical & Biotechnology Industry, Academic & Research Institutes, Contract Research Organizations (CROs)) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Arthritis Monoclonal Antibodies Global Market Report 2022 – By Drug (Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima), By Application (Rheumatoid Arthritis, Osteoarthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Fibromyalgia), By End-Use (Hopitals, Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Cancer Monoclonal Antibodies Global Market Report 2022 – By Monoclonal Antibody Therapies (Bevacizumab (Avastin), Rituximab (Rituxan), Trastuzumab (Herceptin), Cetuximab (Erbitux), Panitumumab (Vectibix)), By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain Cancer, Colorectal Cancer), By End User (Hospitals And Clinics, Research Laboratories, Pharmacies) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Conjugated Monoclonal Antibodies Global Market Report 2022 – By Drugs (Adcetris, Kadcyla), By Technology (Cleavable Linker, Non-cleavable Linker), By Application (Blood Cancer, Breast Cancer, Ovarian Cancer, Lung Cancer, Brain Tumour) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Monoclonal Antibodies (MAbs) Global Market Report 2022 – By Source (Murine, Chimeric, Humanized, Human), By Application (Anti-Cancer, Immunological, Anti-Infective Monoclonal Antibodies (MAbs), Neuropharmacological, Cardiovascular And Cerebrovascular), By End-User (Hospitals, Private Clinics, Research Institute) – Market Size, Trends, And Global Forecast 2022-2026
View Report
Genomics Global Market Report 2022 – By Product Type (Instrument (Including Systems, Service Contract And Software), Reagents (Including Reagents And Consumables)), By Process (Cell Isolation, Sample Preparation, Genomic Analysis), By End User (Academic Institutes, Biopharmaceutical Companies, Clinical Research Institutes) – Market Size, Trends, And Global Forecast 2022-2026
View Report